Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05602376

Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging

This study will evaluate the impact of U=U messaging and counseling on gaps in the HIV care cascade for men, including testing uptake and ART initiation (Aim 1), achieving viral suppression and retention in care (Aim 2) in two provinces in South Africa. The U=U message communicates the compelling idea that PLHIV who take ART and have an undetectable viral load (<200 copies/mL) cannot sexually transmit HIV. Additionally, the investigators will conduct a multi-method evaluation to inform future implementation of U=U messaging interventions (Aim 3).

Recruiting

Interested in participating?

Request Info

Key information

About this study

Increasing the coverage of HIV testing and treatment among people living with HIV (PLHIV) is essential for ending the global AIDS epidemic. Unfortunately, compared to women, men living with HIV (MLHIV) are less likely to know their HIV status, start anti retroviral treatment, or achieve viral suppression. Given that new HIV infections among women are driven, in part, by men's testing and treatment gaps, reducing the gender gap in testing uptake, treatment initiation and achievement of viral suppression by men must be prioritized in order to accelerate the decline in HIV incidence among women, improve men's HIV-related health outcomes and achieve the UNAIDS 95-95-95 goals by 2030.

In this study, the investigators evaluate the effectiveness of Undetectable Equals Untransmittable or "U=U" messaging for closing the gender gap in the HIV cascade. Particularly for men, the U=U message has the potential to accelerate progress towards the 95-95-95 targets by: 1) reducing anxiety associated with HIV testing (1st 95); 2) encouraging people who test HIV positive to initiate ART (2nd 95); and 3) reducing fear of transmitting HIV to sexual partners by promoting treatment adherence to achieve viral suppression (3rd 95). While there is a growing knowledge of Treatment as Prevention (TasP)/U=U among PLWH in Western countries, the reach and penetration of the U=U message in sub-Saharan Africa has been limited and few studies have tested the impacted of accessible U=U messages on ART uptake and adherence in sub-Saharan Africa.

Building on the investigators prior work on U=U messaging informed by behavioral economics and human-centered design, they propose to conduct two hybrid type 1 effectiveness-implementation randomized controlled trials to evaluate the impact of U=U messages on men's uptake of community-based HIV testing and treatment initiation (Aim 1), and achievement of viral suppression (Aim 2). The investigators will also conduct a multi-method evaluation to inform future implementation of U=U messaging interventions. To improve the generalizability of the findings, the study will be conducted in two provinces in South Africa (Western and Eastern Cape). If effective, the intervention can shape global HIV testing and treatment counselling guidelines and practices. The expert, multi-institutional collaborations will allow for the application of previous research findings, leverage unique implementation platforms and resources, and rapidly disseminate the findings.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

AIM 1:

  • male
  • aged ≥15 years
  • present a study issued invitation card to site receptionist
  • ability to provide informed consent.

AIM 2:

  • cis-gender men
  • aged ≥15 years
  • newly initiating ART (i.e., treatment naïve) or re-initiating ART after 6 months of being lost-to-care
  • live in Buffalo City or Cape Town Metro Health Districts
  • provide written informed consent

Treatment and study plan

U=U testing messaging scripts

Behavioral

On site testing days randomized to the intervention, trained health promoters employed by the mobile testing venues will use U=U messaging scripts to invite men in the vicinity to seek HIV testing services on that day. On intervention days, the U=U messaging will also be used by counselors at the testing venue when referring those who test HIV positive to clinic-based ART initiation services provided by the local Department of Health

U=U adherence messaging scripts

Behavioral

After receiving standard ART initiation and adherence counselling from a DoH clinic nurse per South African National Guidelines, RCs will deliver a U=U message and hand participants a small business card with a brief U=U message on it. Participants will then receive monthly SMS booster messages (but can opt out) and monthly in-clinic booster messages during routine medical refill visits, again with a business card for messaging reinforcement.

Primary outcomes

  1. ART initiation among those invited to test for HIV

    Time frame: 30-day follow-up period

    Proportions of ART initiation among all people invited to test in each study arm over the year of Aim 1 data collection

  2. Proportion with viral load suppression

    Time frame: 6-month visit

    Proportions of people who have documented viral suppression at the 6-month visit in each study arm during Aim 2

Secondary outcomes

  1. % who agree to testing

    Time frame: Baseline

    Proportions of testing uptake among all people invited to test in each study arm over the year of Aim 1 enrolment.

  2. Proportion retained in care

    Time frame: 12-month visit

    Proportions of people who have a recorded viral load at their 12-month visit in each study arm during Aim 2.

Study contacts

Contact information is provided by the study sponsor or research team.

Andrew Medina-Marino, PhD

CONTACT

[email protected]

+27 87 821 1109

Sponsors and collaborators

Lead sponsor

Desmond Tutu HIV Foundation

Other

Collaborators

  • National Institute of Mental Health (NIMH)
  • National Institutes of Health (NIH)
  • University of Pennsylvania

Registry information

Important dates

Study start
2023
Primary completion
2026
Study completion
2027
First posted
Nov 2, 2022
Registry last updated
Nov 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.